Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-01-03

Clinical Trial Update: Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial update for brodalumab in adults with moderate to severe Crohn's disease has been terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • brodalumab (brodalumab)

Snippet

Sponsor: Amgen | Conditions: Crohn's Disease | Phase 2 | Status: TERMINATED | Results posted: 2022-01-03